A Randomized Clinical Trial of CCX168, an Orally Administered C5aR Inhibitor for Treatment of Patients with ANCA-Associated Vasculitis

被引：0
|
作者：
Merkel, Peter A. [1 ]
Niles, John [2 ]
Jimenez, Richard [3 ]
Spiera, Robert F. [4 ]
Rovin, Brad H. [5 ]
Bomback, Andrew [6 ]
Pagnoux, Christian [7 ]
Potarca, Antonia [8 ]
Schall, Thomas J. [9 ]
Bekker, Pirow [9 ]
机构：
[1] Univ Penn, Div Rheumatol, Perelman Sch Med, Philadelphia, PA 19104 USA
[2] Massachusetts Gen Hosp, Boston, MA 02114 USA
[3] Univ Washington Med, Northwest Hosp & Med Ctr, Seattle Arthrit Clin, Rheumatol, Seattle, WA USA
[4] Hosp Special Surg, 535 E 70th St, New York, NY 10021 USA
[5] Ohio State Univ, Med Ctr, Columbus, OH 43210 USA
[6] Columbia Univ, Med Ctr, New York, NY USA
[7] Univ Toronto, Univ Hlth Network, Mt Sinai Hosp, Div Rheumatol, Toronto, ON, Canada
[8] ChemoCentryx Inc, Mountain View, CA USA
[9] ChemoCentryx, Mountain View, CA USA
来源：
ARTHRITIS & RHEUMATOLOGY | 2016年 / 68卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
978
引用
收藏
页数：2
相关论文
共 50 条
  • [31] C5AR INHIBITOR AVACOPAN IN ANTI-NEUTROPHIL CYTOPLASMIC AUTOANTIBODY (ANCA) VASCULITIS: PHASE II OUTCOMES OF SAFETY, RENAL PARAMETERS, AND QUALITY OF LIFE
    Schall, Thomas
    Potarca, Antonia
    Hillson, Jan
    Bekker, Pirow
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2018, 71 (04) : 582 - 582
  • [32] Effect of Reduced-Dose vs High-Dose Glucocorticoids Added to Rituximab on Remission Induction in ANCA-Associated Vasculitis A Randomized Clinical Trial
    Furuta, Shunsuke
    Nakagomi, Daiki
    Kobayashi, Yoshihisa
    Hiraguri, Masaki
    Sugiyama, Takao
    Amano, Koichi
    Umibe, Takeshi
    Kono, Hajime
    Kurasawa, Kazuhiro
    Kita, Yasuhiko
    Matsumura, Ryutaro
    Kaneko, Yuko
    Ninagawa, Keita
    Hiromura, Keiju
    Kagami, Shin-ichiro
    Inaba, Yosuke
    Hanaoka, Hideki
    Ikeda, Kei
    Nakajima, Hiroshi
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2021, 325 (21): : 2178 - 2187
  • [33] LONG-TERM FOLLOW-UP OF PATIENTS WITH ANCA-ASSOCIATED VASCULITIS INCLUDED IN EUROPEAN VASCULITIS SOCIETY RANDOMIZED CLINICAL TRIALS SINCE 1995: A SURVIVAL ANALYSIS
    Alamo, Beatriz Sanchez
    Moi, Laura
    Faurschou, Mikkel
    Hauser, Thomas
    Bajema, Ingeborg M.
    Luqmani, Raashid
    Mahr, Alfred
    Cid, Maria
    Hruskova, Zdenka
    Tesar, Vladimir
    Jayne, David
    Westman, Kerstin W. A.
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2021, 36
  • [34] Outcome of rituximab treatment in Japanese patients with ANCA-associated vasculitis in daily clinical practice: A two-centre study in Fukushima, Japan
    Yashiro-Furuya, Makiko
    Sato, Shuzo
    Akanuma, Momo
    Sato, Kairi
    Suzuki, Eiji
    Kanno, Takashi
    Matsumoto, Haruki
    Temmoku, Jumpei
    Fujita, Yuya
    Matsuoka, Naoki
    Asano, Tomoyuki
    Kobayashi, Hiroko
    Watanabe, Hiroshi
    Migita, Kiyoshi
    MODERN RHEUMATOLOGY, 2023, 33 (02) : 352 - 359
  • [35] A Randomized, Double-Blind, Phase II Study of Glucocorticoid Replacement by Vilobelimab, an Anti-C5a Monoclonal Antibody, in ANCA-Associated Vasculitis
    Merkel, Peter
    Hellmich, Bernhard
    Pfaff, Anja
    Muller, Carina
    Startseva, Elena
    Jayne, David
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 1054 - 1055
  • [36] Extended Follow-Up of Patients Recruited to a Randomized, Controlled Trial of Rituximab versus Azathioprine After Induction of Remission with Rituximab for Patients with ANCA-Associated Vasculitis and Relapsing Disease
    Smith, Rona
    Jayne, David
    Merkel, Peter A.
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [37] Avacopan C5a anaphylatoxin chemotactic receptor 1 (C5aR1) antagonist, Treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis
    Pease, J. E.
    DRUGS OF THE FUTURE, 2021, 46 (03) : 183 - 190
  • [38] Insights from the ADVOCATE Study: Respiratory Tract Involvement in Patients with ANCA-Associated Vasculitis in a Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Avacopan
    Specks, U.
    Jayne, D. R. W.
    Merkel, P. A.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2022, 205
  • [39] Remission, Glucocorticoid Toxicity, Health-Related Quality of Life, and Safety Outcomes in Patients with Renal Involvement in the Phase 3 Trial of Avacopan for the Treatment of ANCA-Associated Vasculitis
    Geetha, Duvuru
    Cortazar, Frank
    Bruchfeld, Annette
    Karras, Alexandre
    Merkel, Peter
    Jayne, David
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 1363 - 1364
  • [40] Adjunctive Treatment With Avacopan, an Oral C5a Receptor Inhibitor, in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
    Merkel, Peter A.
    Niles, John
    Jimenez, Richard
    Spiera, Robert F.
    Rovin, Brad H.
    Bomback, Andrew
    Pagnoux, Christian
    Potarca, Antonia
    Schall, Thomas J.
    Bekker, Pirow
    ACR OPEN RHEUMATOLOGY, 2020, 2 (11) : 662 - 671
12345